Drug intelligence / Profile preview

SL-333

Development stage: Preclinical
Lead developer: Gritstone Oncology
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

SL-333 is a preclinical RNA-based neoantigen immunotherapy developed by Gritstone Oncology for the treatment of advanced solid tumors. It utilizes proprietary lipid nanoparticle (LNP) technology from Arbutus Biopharma for in vivo delivery of Gritstone's RNA-encoded neoantigens, aiming to stimulate the immune system to target cancer cells.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on SL-333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SL-333.

Explore the full profile